TIMING - Timing of second dose of SARS-CoV2 mRNA vaccine on immunologic and neutralizing antibody responses generated in healthcare workers [Funder: PHRI]
- Funded by Other Funders (Canada)
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Funder
Other Funders (Canada)Principal Investigator
Darryl and Mylinh and Sumathy Leong and Duong and RangarajanResearch Location
CanadaLead Research Institution
N/AResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Adults (18 and older)
Vulnerable Population
Unspecified
Occupations of Interest
Health Personnel
Abstract
This real-world study is addressing the marked and unexpected reduction in the supply of the mRNA vaccines to Canada, as of January 2021, which has led to a policy change of delaying the second dose of the Pfizer vaccine to healthcare workers (HCW) up to 35 to 42 days. There is little evidence to support this policy, which could be harmful if immunity diminishes to low levels, leaving HCWs at risk of infection before the delayed second dose. Furthermore, there is no data to inform how dosing schedules may impact on the secondary immune responses and long term immunity. However, this policy represents a potential natural experiment and an opportunity to study the impact of dosing schedule on vaccine immunogenicity as it relates to short and long term immunity. Since the sequence and timing interval of dosing to HCWs are largely randomly generated; the variation in time interval between the first and second vaccine doses is unbiased and unaffected by any factors other than by chance.